kurskvestЧеловек и его здоровьеHumans and their health1998-57461998-5754Kursk State Medical Universitykurskvest-94Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEВлияние клеточной терапии на биохимические маркеры сердечной недостаточности у пациентов с ишемической болезнью сердцаEffect of cell therapy on biochemical markers of heart failure in patients with coronary heart diseaseСергиенкоН. В.SergienkoN. V.noemail@neicon.ruНалетоваЕ. Н.NaletovaE. N.noemail@neicon.ruДонецкий национальный медицинский университет им. М. Горького; Институт неотложной и восстановительной хирургии им. В.К. ГусакаРоссияV.K. Gusak Institute of Emergency and Reconstructive Surgery; M. Gorky Donetsk National Medical UniversityRussian FederationДонецкий национальный медицинский университет им. М. ГорькогоРоссияM. Gorky Donetsk National Medical UniversityRussian Federation201615122017015056Copyright © Сергиенко Н.В., Налетова Е.Н., 20172017Сергиенко Н.В., Налетова Е.Н.Sergienko N.V., Naletova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.kursk-vestnik.ru/jour/article/view/94

Представлен опыт внутривенного введения мезенхимальных стволовых клеток (МСК) у пациентов с сердечной недостаточностью на фоне ишемической болезни сердца (ИБС). Аутологичные МСК вводили внутривенно в дозе 50 млн. клеток. Было отмечено увеличение ФВ до 38,6±2,3% и 38,2±2,4% к концу 12 и 24 недели наблюдения соответственно по сравнению с исходным состоянием (35,2±2,5%). К концу 12 недели наблюдения отмечено статистически значимое снижение уровня НУП до значения 311±26 пкг/мл в сравнении с исходным 407±35 пкг/мл и с показателями в контрольной группе. К концу 24 недели наблюдения данная тенденция сохранялась. Уровень лактата сыворотки крови к концу 12 недели наблюдения снижался до значения 4,37±0,28 ммоль/л в сравнении с исходным состоянием (5,08±0,26 ммоль/л). Клеточная терапия в сочетании со стандартной медикаментозной терапией оказывает позитивное влияние на течение ХСН, что подтверждается улучшением основных параметров гемодинамики и снижением уровня биохимических маркеров СН.

This article provides the information on the intravenous administration of mesenchymal stem cells (MSCs) to patients with heart failure against coronary heart disease. Autologous MSCs were injected intravenously in a dose of 50 million cells. We revealed an increase in ejection fraction up to 38.6 ± 2.3% and 38.2 ± 2.4% by the end of the 12th and the 24th weeks respectively as compared with the initial state (35 ± 2.5%). By the end of the 12-week observation we revealed a statistically significant decrease in BNP levels up to 311 ± 26 pg/ml as compared with the initial 407 ± 35 pg/mL on the one hand, and as compared with the control group indices on the other. By the end of the 24-week observation this trend continued. Lactate level by the end of 12-week observation had been decreased by 4.37 ± 0.28 mmol / L compared to the baseline (5.08 ± 0 26 mmol/l). The cell therapy in combination with the standard medical therapy has a positive effect on the course of heart failure.

мозговой натрийуретический пептидлактатсердечная недостаточностьклеточная терапияbrain natriuretic peptideheart failurelactatecell therapyReferencesКудряшев В.Э., Иванов С.В., Белецкий Ю.В. Количественная оценка нарушений кровообращения (пробы с физической на-грузкой) - М. : Медицина, 2000. - 224 с.Кудряшев В.Э., Иванов С.В., Белецкий Ю.В. Количественная оценка нарушений кровообращения (пробы с физической на-грузкой) - М. : Медицина, 2000. - 224 с.Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure// Nature Reviews Cardiology. - 2012. - Vol. 9, N 6. - Р.347-359.Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure// Nature Reviews Cardiology. - 2012. - Vol. 9, N 6. - Р.347-359.Desai A.S. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long // Circulation. - 2013. - Vol. 127. - P.509-516.Desai A.S. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long // Circulation. - 2013. - Vol. 127. - P.509-516.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology [Электронный ресурс] // European Heart Journal. - Режим доступа: https://www.nvvc.nl/media/richtlijn/146, свободный (03.11.13).ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology [Электронный ресурс] // European Heart Journal. - Режим доступа: https://www.nvvc.nl/media/richtlijn/146, свободный (03.11.13).Hare J.M. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial // JAMA. - 2012. - Vol. 308, N 22. - P. 2369-2379Hare J.M. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial // JAMA. - 2012. - Vol. 308, N 22. - P. 2369-2379Horwitz E.M. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement // Cytotherapy. - 2005. - Vol.7, № 5. - P. 393-395.Horwitz E.M. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement // Cytotherapy. - 2005. - Vol.7, № 5. - P. 393-395.Januzzi J.L. Jr., Rehman S.U., Mohammed A.A. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction // J. Am. Coll. Cardiol. - 2011. - Vol. 58, N 18. - P. 1881-1889Januzzi J.L. Jr., Rehman S.U., Mohammed A.A. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction // J. Am. Coll. Cardiol. - 2011. - Vol. 58, N 18. - P. 1881-1889Jeevanantham V. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis // Circulation. - 2012. - Vol. 126. - P.551-568.Jeevanantham V. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis // Circulation. - 2012. - Vol. 126. - P.551-568.Judkins M. P. Selective coronary arteriography. I. A percutaneous transfemoral technic // Radiology. - 1967. - Vol.89, N 5. - P. 815-824.Judkins M. P. Selective coronary arteriography. I. A percutaneous transfemoral technic // Radiology. - 1967. - Vol.89, N 5. - P. 815-824.Ky B., French B., Levy W.C. Multiple biomarkers for risk prediction in chronic heart failure // Circulation: Heart Failure. - 2012. - N 5. - P.183-190.Ky B., French B., Levy W.C. Multiple biomarkers for risk prediction in chronic heart failure // Circulation: Heart Failure. - 2012. - N 5. - P.183-190.Leri A., Anversa P. Stem cells: bone-marrow-derived cells and heart failure-the debate goes on // Nature Reviews Cardiology. - 2013. - № 10. - P.372-373.Leri A., Anversa P. Stem cells: bone-marrow-derived cells and heart failure-the debate goes on // Nature Reviews Cardiology. - 2013. - № 10. - P.372-373.Patel A.N. Francisco S., Winters A.A. Stem cells therapy for heart failure // Heart Failure Clinics. - 2015. - Vol. 11. - P. 275-286Patel A.N. Francisco S., Winters A.A. Stem cells therapy for heart failure // Heart Failure Clinics. - 2015. - Vol. 11. - P. 275-286Petrin E.C., Willerson J.T., Pepine C.J. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial // JAMA. - 2012. - Vol. 307, N 16. - P. 1717-1726.Petrin E.C., Willerson J.T., Pepine C.J. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial // JAMA. - 2012. - Vol. 307, N 16. - P. 1717-1726.Porapakkham P., Porapakkham P., Zimmet H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis // Archives of Internal Medicine. - 2010. - Vol. 170, N 6. - P. 507-514.Porapakkham P., Porapakkham P., Zimmet H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis // Archives of Internal Medicine. - 2010. - Vol. 170, N 6. - P. 507-514.Rector T.S., Kubo S.H., Cohn J.N. Patients' self-assessment oftheir congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire// Heart Failure. - 1987. - Vol. 3. - Р. 198-209.Rector T.S., Kubo S.H., Cohn J.N. Patients' self-assessment oftheir congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire// Heart Failure. - 1987. - Vol. 3. - Р. 198-209.Secunda R. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study // Cytotechnology. - 2015. - Vol. 67, N 5. - P. 793-807.Secunda R. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study // Cytotechnology. - 2015. - Vol. 67, N 5. - P. 793-807.Tang Y.L., Wang Y.J., Chen L.J., Pan Y.H., Zhang L., Weintraub N.L. Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications // Experimental Biology Medicine (Maywood). - 2013. - Vol. 238, N 3. - P. 294-300.Tang Y.L., Wang Y.J., Chen L.J., Pan Y.H., Zhang L., Weintraub N.L. Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications // Experimental Biology Medicine (Maywood). - 2013. - Vol. 238, N 3. - P. 294-300.Troughton R.W., Frampton C.M., Nicholls M.G. Biomarker-guided treatment of heart failure: still waiting for a definitive answer // J. Am. Coll. Cardiol. - 2010. - Vol. 56. - P. 2101-2104.Troughton R.W., Frampton C.M., Nicholls M.G. Biomarker-guided treatment of heart failure: still waiting for a definitive answer // J. Am. Coll. Cardiol. - 2010. - Vol. 56. - P. 2101-2104.Watson N.C., Heard O.S. The use of lactate as a biomarker // J. Intensive Care Med. - 2010. - Vol. 25, N 5. - P. 301-302.Watson N.C., Heard O.S. The use of lactate as a biomarker // J. Intensive Care Med. - 2010. - Vol. 25, N 5. - P. 301-302.

The authors declare that there are no conflicts of interest present.